Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Zagadailov · SciRah

Researcher profile · Semantic Scholar

E. Zagadailov

Share profile

E. Zagadailov — researcher profile on SciRah

h-index: 13
Works: 53
Citations: 1,058

Most-cited papers

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
H. Prince, Youn H. Kim, S. Horwitz, R. Dummer +29 more
2017The Lancet542 citations
Semantic Scholar
Epidemiology of clinically significant forms of alpha‐ and beta‐thalassemia: A global map of evidence and gaps
K. Musallam, L. Lombard, K. Kistler, María Arregui +5 more
2023American journal of hematology/oncology104 citations Open access
Semantic Scholar
Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Hanny T. Al-Samkari, F. Galactéros, A. Glenthøj, J. Rothman +15 more
2022New England Journal of Medicine68 citations Open access
Semantic Scholar
Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
P. Bröckelmann, S. McMullen, J. Ben Wilson, Kerstin Mueller +7 more
2018British Journal of Haematology50 citations Open access
Semantic Scholar
Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.
E. Zagadailov, M. Fine, A. Shields
2013American health & drug benefits48 citations
Semantic Scholar
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
A. Glenthøj, E. V. van Beers, H. Al-Samkari, V. Viprakasit +11 more
2022The Lancet Haematology34 citations Open access
Semantic Scholar
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
R. Dummer, H. Prince, S. Whittaker, S. Horwitz +23 more
2020European Journal of Cancer29 citations Open access
Semantic Scholar
OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)
T. Owonikoko, K. Nackaerts, T. Csőszi, G. Ostoros +7 more
201723 citations Open access
Semantic Scholar
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.
S. Ailawadhi, M. DerSarkissian, M. Duh, M. Lafeuille +5 more
2019Clinical Therapeutics20 citations
Semantic Scholar
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study
P. Bröckelmann, E. Zagadailov, S. Corman, Viktor Chirikov +5 more
2017European Journal of Haematology20 citations Open access
Semantic Scholar
Real-world effectiveness of brentuximab vedotin versus physicians’ choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany
E. Zagadailov, S. Corman, Viktor Chirikov, Courtney Johnson +5 more
2018Leukemia and Lymphoma19 citations Open access
Semantic Scholar
Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study
Youn H. Kim, S. Whittaker, S. Horwitz, M. Duvic +12 more
201618 citations
Semantic Scholar
Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases
B. Seal, S. Sullivan, S. Ramsey, C. Asche +5 more
2014Applied Health Economics and Health Policy14 citations Open access
Semantic Scholar
The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review
M. Dalal, S. Mitchell, C. McCloskey, E. Zagadailov +1 more
2020Expert Review of Hematology13 citations Open access
Semantic Scholar
Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea.
T. Williamson, R. Kamalakar, A. Ogbonnaya, E. Zagadailov +2 more
2017American health & drug benefits10 citations
Semantic Scholar
Transplant Coordinators' Perceived Impact of Availability of Multiple Generic Immunosuppression Therapies on Patients, Workload, and Posttransplant Maintenance Therapy
K. Parker, E. Zagadailov, A. Bruno, A. Wiland
2013Journal of Transplantation7 citations Open access
Semantic Scholar
Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting.
B. Seal, S. Sullivan, S. Ramsey, C. Asche +5 more
2015Future Oncology6 citations
Semantic Scholar
Real-world effectiveness of brentuximab vedotin vs other treatments in patients with relapsed/refractory Hodgkin lymphoma post autologous stem-cell transplantation.
E. Zagadailov, S. Corman, M. Hagan, Viktor Chirikov +6 more
20165 citations
Semantic Scholar
Long-Term Improvements in Patient-Reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
K. Kuo, R. Grace, E. V. van Beers, W. Barcellini +7 more
2022Blood4 citations Open access
Semantic Scholar
Validation of the Pyruvate Kinase Deficiency Impact Assessment (PKDIA): A Patient-Reported Outcome Measure for Pyruvate Kinase (PK) Deficiency
S. Egan, E. Zagadailov, A. Jewett, Jun-Long Li +3 more
2021Blood4 citations Open access
Semantic Scholar
Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat
A. Gautam, Yanyan Zhu, E. Ma, Shih‐Yuan Lee +5 more
2018Leukemia and Lymphoma4 citations
Semantic Scholar
Validation of the Pyruvate Kinase Deficiency Diary (PKDD): A Patient-Reported Outcome Measure for Pyruvate Kinase (PK) Deficiency
S. Egan, E. Zagadailov, A. Jewett, Jun-Long Li +3 more
2021Blood3 citations Open access
Semantic Scholar
P1476: THE CLINICAL CHARACTERISTICS AND OVERALL SURVIVAL OF PATIENTS WITH PYRUVATE KINASE DEFICIENCY IN THE UK: A REAL-WORLD STUDY
S. Higa, K. Keapoletswe, L. Cirneanu, S. Hagenaars +2 more
2023HemaSphere2 citations Open access
Semantic Scholar
Mortality Among Veterans with a Diagnosis of Pyruvate Kinase (PK) Deficiency: A Real-World Study Using US Veterans Health Administration Data
E. Zagadailov, A. Boscoe, V. Garcia-Horton, Sherry Shi +3 more
20202 citations
Semantic Scholar
Evaluating the Cost of Treating Bladder Cancer With and Without Metastases
B. Seal, K. Shermock, C. Asche, Jane Chang +6 more
20152 citations Open access
Semantic Scholar
Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
S. Ailawadhi, M. DerSarkissian, M. Duh, M. Lafeuille +5 more
20171 citations
Semantic Scholar
262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study
Youn H. Kim, S. Whittaker, S. Horwitz, M. Duvic +12 more
20171 citations Open access
Semantic Scholar
Treatment Outcomes Of Relapsed/ Refractory Hodgkin’s Lymphoma Post-Asct: A Systematic Review
E. Zagadailov, N. Halfpenny, A. Taylor, Jc Thompson
20161 citations Open access
Semantic Scholar
Brentuximab vedotin in patients who are ineligible for autologous stem cell transplant with relapsed or refractory Hodgkin lymphoma: a United Kingdom and Germany retrospective study.
P. Bröckelmann, E. Zagadailov, S. Corman, M. Hagan +6 more
20161 citations
Semantic Scholar
Cost of Care for Gastric Cancer In Patients With and Without Metastases
K. Shermock, C. Asche, B. Seal, C. Kreilick +5 more
20151 citations Open access
Semantic Scholar
THE IMPLICATIONS OF USING A 30-, 60-, OR 90-DAY GAP IN TREATMENT TO SPECIFY LINES OF CARE IN GASTRIC CANCER TREATMENT
B. Seal, K. Shermock, C. Asche, C. Kreilick +4 more
20151 citations Open access
Semantic Scholar
Use Of Work Productivity Endpoints In Clinical Studies: A Review By Disease State And Measurement Type
B. Popelar, T. Walters, E. Zagadailov, C. Houle +1 more
20151 citations Open access
Semantic Scholar
Recent Health Technology Assessment Decisions Across The Globe: A Focus On Oncology
R. Clark, E. Zagadailov, T. Bramley
20141 citations Open access
Semantic Scholar
PB2547: ESTIMATING HEALTH-RELATED QUALITY OF LIFE IN ADULT PYRUVATE KINASE DEFICIENCY: A TIME TRADE-OFF UTILITY STUDY
S. Higa, G. Chua, A. Sussex, A. Lloyd +4 more
2023HemaSphere0 citations Open access
Semantic Scholar
RWD25 Patient Characteristics and Healthcare Resource Utilization of Patients with Pyruvate Kinase Deficiency in a United States Electronic Health Record Database
S. Higa, E. Zagadailov, A. Anderson, J. Seare +1 more
2022Value in Health0 citations Open access
Semantic Scholar
PB2359: HEALTHCARE RESOURCE UTILIZATION OF ADULT PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A REAL WORLD STUDY USING US VETERANS HEALTH ADMINISTRATION DATA
E. Zagadailov, V. Garcia-Horton, S. Higa, L. Shi
2022HemaSphere0 citations Open access
Semantic Scholar
PCN101 - COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH MAINTENANCE THERAPY IN MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW
D. Cherepanov, S. Kayaniyil, H. Huang, D. Romanus +3 more
2018Value in Health0 citations Open access
Semantic Scholar
Use of Brentuximab Vedotin to Treat Hodgkin Lymphoma in a Private Sector Setting in Brazil
F. Andrade, T. Barreto, E. Zagadailov, A. Gautam +5 more
20170 citations Open access
Semantic Scholar
Is Durability of Response Reported in Refractory CTCL: A Systematic Review
M. Dalal, S. Mitchell, C. McCloskey, E. Zagadailov +1 more
20170 citations
Semantic Scholar
Long‐term quality of life in patients with advanced Hodgkin lymphoma: A systematic review
M. Dalal, S. A. Mitchell, C. McCloskey, E. Zagadailov +1 more
20170 citations Open access
Semantic Scholar
Brentuximab vedotin (BV) consolidation post-autologous stem cell transplant (ASCT) in patients (pts) with Hodgkin lymphoma (HL) at risk of residual disease: Number needed to treat (NNT) analysis.
A. Gautam, D. Huebner, Yanyan Zhu, E. Ma +5 more
2016Journal of Clinical Oncology0 citations
Semantic Scholar
Adherence to guideline-recommended chemotherapy in the treatment of gastric cancer.
J. Kish, B. Seal, K. Shermock, C. Asche +4 more
20150 citations
Semantic Scholar
Evaluating patterns of care in the treatment of bladder cancer with and without metastases.
E. Zagadailov, B. Seal, K. Shermock, C. Asche +6 more
20150 citations
Semantic Scholar
Surgical, radiological, and chemotherapy treatment patterns for non-metastatic and metastatic gastric cancer.
K. Shermock, B. Seal, C. Asche, Jane Chang +4 more
20150 citations
Semantic Scholar
Adherence to chemotherapy guidelines for non-metastatic (NM) and metastatic (M) colorectal cancer (CRC).
B. Seal, K. Shermock, C. Asche, Jane Chang +4 more
20150 citations
Semantic Scholar
Rate of adverse event-related treatment changes and Healthcare costs associated with topical Rosacea treatment
T. Williamson, R. Kamalakar, A. Ogbonnaya, J. Kish +3 more
20150 citations Open access
Semantic Scholar
Patterns of Care In The Workup And Management of Non-Metastatic And Metastatic Colorectal Cancer
B. Seal, K. Shermock, C. Asche, C. Kreilick +5 more
20150 citations Open access
Semantic Scholar
Evaluating Costs and Utilization of Prostate Cancer Patients with Bone Metastases in the Outpatient Hospital Setting
B. Seal, E. Zagadailov, E. Farrelly, C. Asche +4 more
20140 citations Open access
Semantic Scholar
An evaluation of national treatment trends and survival in GIST.
D. Stafkey-Mailey, B. Seal, Fang Xia, Petra Rietschel +4 more
20140 citations
Semantic Scholar
Budget impact of phentermine and topiramate extended-release (PHEN/TPM ER) in overweight and obese patients with comorbid prediabetes or type 2 diabetes mellitus (T2DM)
E. Zagadailov, R. Carlton, T. Bramley, W. Liu +2 more
20140 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Seal×16
Invite
B. Seal — researcher profile on SciRah
C. Asche×12
Invite
C. Asche — researcher profile on SciRah
K. Shermock×10
Invite
K. Shermock — researcher profile on SciRah
M. Dalal×9
Invite
M. Dalal — researcher profile on SciRah

×8

Invite

M. Eaddy — researcher profile on SciRah

Invite

C. Kreilick — researcher profile on SciRah

Invite

J. Kish — researcher profile on SciRah

Invite

A. Gautam — researcher profile on SciRah

Invite

Jane Chang — researcher profile on SciRah

Invite

M. Eaddy — researcher profile on SciRah

Invite

D. Huebner — researcher profile on SciRah

Invite

T. Illidge — researcher profile on SciRah